EXCLUSIVE: Maximum NHS Fife payout to nurse at centre of trans tribunal revealed
Kirkcaldy medic Sandie Peggie is suing the health board after she was suspended following a row with trans doctor Beth Upton on Christmas Eve in 2023.
No settlement has been reached between the two parties.
According to details obtained by The Courier under Freedom of Information laws, the five-figure sum is the absolute maximum NHS Fife would be liable for.
If Ms Peggie is to be awarded more than £25,000, the rest of the money will come from a national risk scheme designed to protect NHS boards from heavy losses.
The Courier reported in March that the health board was only responsible for 'part' of the legal bill for the hearing.
We can also reveal NHS Fife has spent a total of £184,000 this year on six separate employment tribunals, covering legal fees and any settlements.
NHS Fife refused to say how much it has spent on Ms Peggie's tribunal, meaning the overall cost remains unknown.
On Wednesday, the health board was criticised by Scottish Information Commissioner David Hamilton for its 'poor handling' of FOI requests linked to spending.
Mr Hamilton said he was 'frustrated' by NHS Fife's approach which had led to an 'unnecessary delay'.
He ruled that the health board failed to do any proper checks to find the information requested.
NHS Fife previously claimed it could not provide the total sum spent on the case because this would disclose personal information.
Mr Hamilton disagreed.
'The commissioner cannot accept that the specific information requested can be the personal data of either of the individuals party to the tribunal,' he wrote.
'The costs are the authority's, not theirs.'
A spokesperson for NHS Fife said: 'NHS Fife notes the report from the Scottish Information Commissioner and intends to comply fully with its decision notice.'
In January 2024, we reported that NHS Fife's total costs on legal claims had passed £1.8 million in five years.
The health board had to spend more than £180,000 on one single claim by a patient.
The NHS Fife trans row employment tribunal in Dundee is set to resume on July 16.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
an hour ago
- Daily Record
Scottish Labour leader hits out at Stirling candidate's ADHD diagnosis wait
In an interview with the Observer, Anas Sarwar labelled the three-year wait for his Stirling candidate's family "heart-breaking" - and called for greater "transparency" from the Scottish Government on mental health waiting times. Scottish Labour leader Anas Sarwar has labelled a three-year wait for crucial mental health support for the son of his Stirling candidate as 'heartbreaking' - and said ministers required more transparency about the scale of the issue. The Observer shared last week the story of the issues faced by the family of Dr Kainde Manji - standing in the Holyrood poll for the seat next year - as she urged other parents and carers to share their stories with an inquiry into ADHD and autism support. The Scottish Parliament Health, Social Care and Sport Committee is undertaking an inquiry into Attention Deficit and Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) pathways and support. Dr Manji said her son had been waiting for a diagnosis for ASD since P1 and the family were no closer to answers three years on. Speaking exclusively to the Observer on a visit to the Riverbank Resource Centre to meet centre users and see the work of local charity Artlink Central - Mr Sarwar was critical of Scottish Government efforts to tackle the issue of mental health waiting lists. He said: 'It's a heartbreaking case, but as Kainde will testify, it's not an isolated one. 'This is a situation impacting families across the country; I was at an ADHD group in Dundee where people were really struggling, parents telling stories of the issues trying to get people diagnosed and being forced to go private. 'Many can't afford to borrow from friends or family to go private and they shouldn't have to. We need to make sure we are doing the appropriate intervention both in terms of getting the diagnosis and then the adequate treatment pathways required. It also needs to be recognised the knock-on impact that has on education and home life. The issue requires a holistic approach with joined-up thinking with a government that is serious about doing its job properly.' Mr Sarwar also took aim at the categorisation of some young people's mental health cases, with health chiefs in Forth Valley among those across Scotland in stating some cases are dealt with by paediatric services and not within CAMHS (Child and Adolescent Mental Health Services). 'I think the government withdrawing ADHD and autism from the CAMHS waiting times is a big part of the problem so what we need is honesty and transparency about the waiting times,' he continued. 'We have to be really careful that we compare like-with-like and don't have government manipulation of statistics to tell a different story from the reality on the ground. 'If they are going to withdraw ADHD and autism from CAMHS waiting lists, then they must be transparent about the length of waiting time, the speed of diagnosis and treatment plans for those people but right now, that is not what is happening.' In response to Mr Sarwar's remarks, Mental Wellbeing Minister Tom Arthur said: 'Child and Adolescent Mental Health Services (CAMHS) support children and young people experiencing significant mental health problems. "CAMHS is not the correct service for children seeking support and a diagnosis for a neurodevelopmental condition, such as ADHD, unless they have a co-existing mental health condition. 'While we are meeting our targets for CAMHS, I am clear that long waits for support, particularly for children, are unacceptable. "We recognise there has been an increased demand for neurodevelopmental support and that is why we are providing an additional £500,000 this year to improve access to care for children, young people and families. 'We expect health boards to deliver services in a way that ensures children receive the right support from specialists – and as quickly as possible – and we are also continuing to work with health boards and local authorities to improve the quality of data available.' Responding to Dr Manji's case and comments, an NHS Forth Valley spokeswoman said: 'Significant investment has been made in developing and improving mental health services and support for children and young people across the area. 'This, along with other changes, has led to NHS Forth Valley having some of the lowest waiting times in Scotland for CAMHS and meeting or exceeding the national target since February 2024. Ninety per cent of children and young people referred are seen within 18 weeks. 'However, like other NHS Boards across Scotland, we have seen a significant increase in referrals for children with neurodevelopmental conditions such as autism or ADHD. 'These children are normally referred to our paediatric service not CAMHS unless they also have a mental health condition. 'Due to the large increase in demand, some families are experiencing longer waiting times for neurodevelopment services and work is currently underway to explore options to increase capacity and reduce waiting times. However, it is important to highlight that families do not need a formal diagnosis of autism or ADHD to access additional support for their child as a range of services and support for children with neurodevelopment conditions is provided by local councils, education and some charitable organisations.'
Daily Record
an hour ago
- Daily Record
NHS update for people with heart and CVD problems explained
New draft guidance from the National Institute for Health and Care Excellence will see six online platforms conditionally recommended to support adults Heart patients will be able to undertake rehabilitation online from their own homes instead of waiting for face-to-face appointments after several platforms received conditional approval for NHS use. Specialists said the programmes 'offer real potential to transform' how this type of care is delivered. Six online platforms have been conditionally recommended to support adults with cardiovascular disease (CVD) in new draft guidance from the National Institute for Health and Care Excellence (NICE). These are Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv and myHeart. CVD is a general term for conditions that impact the heart or blood vessels. It is estimated to impact approximately seven million people in the UK. Even still, according to NICE, uptake for cardiac rehabilitation programmes, which can reduce the risk of further heart problems and hospital admissions, is low. Each platform is now designed to offer cardiac rehabilitation online, including exercise programmes, diet advice, medication management, and psychological support. Some of the platforms also include wearable devices to monitor activity levels. Dr Anastasia Chalkidou, healthtech programme director at NICE, said: "These digital platforms offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances. "We know that traditional programmes aren't reaching everyone who could benefit – particularly women, younger patients and people from ethnic minority backgrounds." Before the online platforms are offered as an option, patients must be assessed by a healthcare professional. NICE suggests that further support may be needed for older people, those with disabilities, homeless patients, or those whose first language is not English. The six platforms will be used on the NHS over the next three years to generate more evidence and data on their long-term effectiveness. Dr Chalkidou added: "The early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies. "This three-year evidence collection period will give us the additional robust data we need to determine whether these innovations should be recommended as a permanent part of cardiac care." A consultation on the conditional recommendation is now underway and will close on September 3. NICE said seven other platforms - Beat Better, Datos Health, Get Ready, Luscii Vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health, and Sword Move - require more research before they can be funded by the NHS.
The Sun
an hour ago
- The Sun
Thousands more Brits to be offered weight loss jabs for free as NHS relaxes rules – are you eligible?
HUNDREDS of thousands more Brits could be offered weight loss jabs on the NHS in the biggest shake up of diabetes care in a decade - as the health service prepares to ease rules around prescriptions. Under new proposed guidance, people with type 2 diabetes in England would be given Ozempic and new diabetes drugs sooner, rather than keeping them for later stages of treatment. 1 Draft guidance from the National Institute for Health and Care Excellence (NICE) stated that the NHS should rethink its one-size-fits-all approach of starting everyone on the same medication. Instead, it should offer patients more personalised care to prevent complications like heart failure and heart attacks. Officials estimate the changes could save almost 22,000 lives. Prof Jonathan Benger, the deputy chief executive and chief medical officer at NICE, said they would mean 'more people will be offered medicines where it is right to do so'. Under the guidance, doctors would be encouraged to prescribe GLP-1 receptor agonists such as liraglutide or semaglutide to diabetes patients who also have heart disease or obesity. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand - Wegovy - is used to help obese people lose weight. Patients would be offered the drugs - which have also been shown to boost heart health - at diagnosis, rather than trying out other medications first. Around 754,000 patients with cardiovascular disease (CVD) or early-onset diabetes could benefit from the proposed changes on weight loss drug prescriptions, NICE said. The guidance says the jabs should be considered in diabetes patients who have also been diagnosed with heart disease, heart failure, or have early onset type 2, which means they were diagnosed before age 40. People with both diabetes and obesity – a body mass index (BMI) over 35 – will also be able to get the jabs if they have not had success in bringing down their blood sugar levels within the first three months of using another drug. NICE also called for making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option for patients. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by NICE found these drugs are under-prescribed, particularly to women, older people, and black patients. Prof Benger said: "The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. "The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications." The new guidelines recommend patients who can't tolerate metformin - the first-choice in type 2 diabetes medication - should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, NICE said. Around 2.3 million people with type 2 diabetes are thought to be eligible for SGLT2's. Wegovy vs Ozempic - what's the difference? Ozempic is often used as a catch-all term for weight loss drugs, but the drug - whose active ingredient is semaglutide - is actually prescribed to treat type 2 diabetes and has the added benefit of making users lose weight. Its manufacturer Novo Nordisk later released a higher dose of semaglutide under the brand name Wegovy to treat obesity. Using Ozempic for weight loss would mean you're using it 'off label' and not for its intended purpose. Not only could that be dangerous to you, it could also mean you're depriving diabetes patients from vital medication. Wegovy and Ozempic are in a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RA). They work by mimicking the GLP-1 hormone produced naturally by your gut when you eat food, which signals to the brain that you're full and prevents you from overeating Prof Benger added: "This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. "This represents a significant evolution in how we approach type 2 diabetes treatment. "We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. "The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. "This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes." Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. The proposed changes won't be instituted just yet, as a public consultation on the NICE guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: "This long-awaited announcement propels type 2 diabetes treatment into the 21st century. "Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. The 7 fat jab mistakes stopping you losing weight WHILE weight loss jabs have been hailed as a breakthrough in helping tackle Britain's obesity crisis, some users say they're missing out on their waist-shrinking powers - and it could be down to some simple mistakes... POOR PENMANSHIP Many people don't correctly use the injection pen, according to Ana Carolina Goncalves, a pharmacist at Pharmica in Holborn, London. Make sure to prime your weight loss pen correctly, as per the instructions. If nothing comes out, try again, and if it still doesn't work, switch the needle or ask a pharmacist for help. It's also recommended to rotate injection sites between the abdomen, thigh and upper arm to avoid small lumps of fat under the skin. TIME IS OF THE ESSENCE Make sure you're using the jabs on the most effective day of your schedule. For example, taking the jab right before a takeaway or party won't stop you from indulging, says Jason Murphy, head of pharmacy and weight loss expert at Chemist4U. Weight loss injections need time to build up in your system, so if you're planning for a heavier weekend, inject your dose mid-week. MAKING A MEAL OF IT You may not feel the urge to overeat at mealtimes due to the jabs. But skipping meals altogether can backfire, says Dr David Huang, director of clinical innovation at weight loss service Voy. If a person is extremely malnourished, their body goes into emergency conservation mode, where their metabolism slows down. FOOD FOR THOUGHT A key mistake using weight loss jabs is not eating the right foods. As well as cutting out sugary drinks and alcohol, Dr Vishal Aggarwal, Healthium Clinics recommends focusing on your protein intake. DE-HYDRATION STATIONS Dehydration is a common side effect of weight loss injections. But it's important to say hydrated in order for your body to function properly. Dr Crystal Wyllie, GP at Asda Online Doctor, says hydration supports metabolism, digestion, and can reduce side effects like headaches, nausea and constipation. MOVE IT, MOVE IT It can be easy to see the jabs as a quick fix, but stopping exercising altogether is a mistake, says Mital Thakrar, a pharmacist from Well Pharmacy. Exercise helps maintain muscle mass and help shape the body as you lose weight, which may be crucial if you're experiencing excess skin. QUIT IT While there's the tendency to ditch the jabs as soon as you reach your desired weight, stopping them too soon can cause rapid regain. Mr Thakrar recommends building habits like healthier eating during treatment for sustaining results. "The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. "Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. "These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes." Earlier this month, drug maker Eli Lilly would hike up the price of its weight loss jab Mounjaro from September 1, meaning the price of the drug in UK private clinics will almost double. Patients have been scrambling to get their hands.
